| Literature DB >> 33076469 |
Mrinalini Dey1,2, Maurizio Cutolo3, Elena Nikiphorou4.
Abstract
BACKGROUND: The role of nutrition in the pathogenesis of rheumatic diseases, including rheumatoid arthritis (RA), has gained increasing attention in recent years. A growing number of studies have focussed on the diverse nutritional contents of beverages, and their possible role in the development and progression of RA. Main body: We aimed to summarise the current knowledge on the role of a range of beverages in the context of RA. Beverages have a key role within the mosaic of autoimmunity in RA and potential to alter the microbiome, leading to downstream effects on inflammatory pathways. The molecular contents of beverages, including coffee, tea, and wine, have similarly been found to interfere with immune signalling pathways, some beneficial for disease progression and others less so. Finally, we consider beverages in the context of wider dietary patterns, and how this growing body of evidence may be harnessed by the multidisciplinary team in patient management.Entities:
Keywords: beverage; microbiome; nutrition; rheumatoid arthritis
Mesh:
Substances:
Year: 2020 PMID: 33076469 PMCID: PMC7602656 DOI: 10.3390/nu12103155
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Nutritional factors found in beverages can alter the composition of the human gut microbiome, resulting in dysbyosis. Interactions between gut microbiota and the immune system are complex, involving many molecular mechanisms. An example is suppression of anti-inflammatory regulatory T (Treg) cells and induction of T helper 17 (TH17) cell differentiation, which can increase susceptibility to autoimmune diseases. (Adapted from [9])
Dietary reference values for carbohydrates, dietary fibre, total fat, fatty acids, protein and water.
| Nutrient | Age Range (Years)/Physiological State | |||||
|---|---|---|---|---|---|---|
| ≥18 | Pregnancy | Lactation | ||||
| 1st Trimester <12 Weeks | 2nd Trimester 13 < 28 Weeks | 3rd Trimester ≥ 28 Weeks | 0–6 Months Post-Partum | >6 Months Post-Partum | ||
| Total carbohydrates a (E%) | 45–60 | |||||
| Dietary fibre b (g/day) | 25 | |||||
| Total fat a (E%) | 20–35 | 20–35 | 20–35 | |||
| SFA | ALAP | ALAP | ALAP | |||
| LA b (E%) | 4 | 4 | 4 | |||
| ALA b (E%) | 0.5 | 0.5 | 0.5 | |||
| EPA + DHA b (mg/day) | 250 | 250 | 250 | |||
| DHA b (mg/day) | +100–200 c | +100–200 c | ||||
| TFA | ALAP | ALAP | ALAP | |||
| Protein | ||||||
| AR d | 0.66 | +0.52 e g/day | +7.2 e g/day | +23 e g/day | +10 e g/day | +15 e g/day |
| PRI d (g/kg bw/day) | 0.83 | +1 f g/day | +9 f g/day | +28 f g/day | +19 f g/day | +23 f g/day |
| Water b,g (L/day) | ||||||
| Males | 2.5 | |||||
| Females | 2.0 | 2.3 | 2.7 | |||
ALA, a-linolenic acid; ALAP, as low as possible; AR, average requirement; DHA, docosahexanoic acid; EPA, eicosapentaenoic acid; E%, percentage of energy intake; L, litre; LA, linoleic acid; PRI, population reference intake; SFA, saturated fatty acids; TFA, trans-fatty acids. a RI, reference intake range, b AI, adequate intake, c in addition to combined intakes of EPA and DHA of 250 mg/day, d to be multiplied by reference body weights to calculate values in g/day, e in addition to AR for protein of non-pregnant, non-lactating women, f in addition to PRI for protein of non-pregnant, non-lactating women, g includes water from beverages of all kind, including drinking and mineral water, and from food moisture. (European Food Safety Authority, 2017. Based on Cutolo, M. and Nikiphorou, E. 2019 ‘EULAR Online Course on Rheumatic Diseases: Nutrition in Rheumatic Diseases’, Module 42d.).
Figure 2Effect of epigallocatechin-3-gallate (EGCG) on inflammation. EGCG modulates intracellular signalling pathways via the 67 kDa laminin receptor (67LR). This reduces mitochondrial production of reactive oxygen species, leading to reduction in pro-inflammatory cytokine production, including NFκβ. This has multiple downstream effects, including downregulation of TNFα, IL-1β, cyclo-oxygenase-2 (COX-2), and matrix metalloproteases (MMP), such as MMP-9.
Figure 3Anti-inflammatory properties of resveratrol. Resveratrol has been shown to inhibit several pro-inflammatory pathways, reducing expression of factors such as NFκβ and caspase-3. It also leads to upregulation of anti-inflammatory molecules including SOX-9 and SIRT1.